GoKawiilCDC gives no recommendation for newly FDA-approved mFlusiva flu vaccine
The FDA approved mFlusiva, a flu vaccine shown to perform well in older adults, but the CDC has issued no formal recommendation on its use. This departs from the agency's usual practice of guiding doctors and the public on newly approved vaccines shortly after FDA clearance.
GoKawiil's interpretation of the reporting above, not reported fact.
The gap suggests the CDC's vaccine advisory process has been disrupted, according to Yale researcher Jason Schwartz, who says there is no clear mechanism to formalize new vaccine guidance even when evidence supports it. This stall, tied to Health Secretary Robert F. Kennedy Jr.'s efforts to change vaccine policy and resulting legal disputes, could leave doctors and patients without clear direction on newly approved shots, potentially affecting how well people are protected against preventable illness.
- FDA approved mFlusiva flu vaccine, but CDC has not issued a usage recommendation
- The absence of CDC guidance breaks from the agency's normal post-approval process
- Experts link the delay to broader disruption of CDC vaccine policy under RFK Jr.
Source: fastcompany.com, 2026-09-25
Published there as: “The FDA approved the new mFlusiva flu vaccine, but the CDC isn’t recommending it. Here’s why”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.